Locally advanced or metastatic NSCLC for which standard anti-cancer treatment is no longer available or indicated. Only MET exon 14 skipping mutations, second-line treatment after immunotherapy and/or platinum-based chemotherapy. Here, MET is linked to non-small cell lung carcinoma.